Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethyl Hydrogen Phosphate SCHEMBL11437635 | 0.88 | CDC25A (0.55) | CDC25AMEN1GAAKMT2ACTDSP1 | |
| SCHEMBL19821341 | 0.84 | CDC25A (0.41) | CDC25ATSHRTERTUCHL3AKT1 | |
| SCHEMBL19821346 | 0.84 | CDC25A (0.38) | CDC25ATSHRTERTUCHL3AKT1 | |
| SCHEMBL19821337 | 0.83 | CDC25A (0.43) | CDC25ATSHRTERTUCHL3AKT1 | |
| Diethyl Hydrogen Phosphate SCHEMBL829439 | 0.72 | CDC25A (0.42) | CDC25ATSHRTERTUCHL3AKT1 | |
| SCHEMBL19821336 | 0.71 | CDC25A (0.33) | CDC25ATSHR | |
| Diethyl Hydrogen Phosphate SCHEMBL830252 | 0.70 | CDC25A (0.44) | CDC25AKMT2ATSHRTERTUCHL3 | |
| SCHEMBL4904748 | 0.70 | CDC25A (0.35) | CDC25ACTDSP1L3MBTL1USP2PABPC1 | |
| SCHEMBL13996422 | 0.70 | CDC25A (0.38) | CDC25AUSP2PABPC1 | |
| Diethyl Hydrogen Phosphate SCHEMBL28780967 | 0.69 | CDC25A (0.47) | CDC25AKMT2ATSHRTERTUCHL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | MODERNATX, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230330260-A1 | RNA FORMULATIONS | ModemaTX, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11786607-B2 | RNA formulations | MODERNATX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-11649461-B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | MODERNATX, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | CDC25A 3971/4885MEN1 4499/4885GAA 1492/4885 |
| US-11786607-B2 | RNA formulations | SYNCRIP, NSUN3, RNMT | CDC25A 4600/4885MEN1 3367/4885GAA 2613/4885 |
| US-20230330260-A1 | RNA FORMULATIONS | SYNCRIP, NSUN3, RNMT | CDC25A 4600/4885MEN1 3367/4885GAA 2613/4885 |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | CFTR, SLC47A1, TMEM205 | CDC25A 3971/4885MEN1 4499/4885GAA 1492/4885 |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | CDC25A 4651/4885MEN1 4443/4885GAA 945/4885 |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | GBA1, GAA, GLA | CDC25A 3408/4885MEN1 4267/4885GAA 2/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CDC25A 4271/4885MEN1 3349/4885GAA 1614/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CDC25A 4271/4885MEN1 3349/4885GAA 1614/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | CDC25A 2859/4885MEN1 4470/4885GAA 1336/4885 |
| US-11649461-B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | GBA1, GAA, GLA | CDC25A 3534/4885MEN1 4286/4885GAA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.